• +1-646-491-9876
    • +91-20-67278686

    Search

    Metachromatic Leukodystrophy-Pipeline Review H1 2017

    Metachromatic Leukodystrophy-Pipeline Review H1 2017

    • Report Code ID: RW0001834373
    • Category Pharmaceuticals
    • No. of Pages 35
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2017, provides an overview of the Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline landscape.

    Metachromatic leukodystrophy is an inherited disorder characterized by the accumulation of fats called sulfatides in cells. Symptoms include vision problems leading to blindness, personality changes, and motor disturbances such as clumsiness, muscle weakness (hypotonia) , rigidity, inability to coordinate movement (ataxia) , and/or muscle spasms especially of the neck, spine, arms, and legs. Treatment for metachromatic leukodystrophy is symptomatic and supportive.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Metachromatic Leukodystrophy (MLD) (Central Nervous System) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Metachromatic Leukodystrophy (MLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

    Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Metachromatic Leukodystrophy (MLD) (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Metachromatic Leukodystrophy (MLD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Metachromatic Leukodystrophy (MLD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Metachromatic Leukodystrophy (MLD) (Central Nervous System) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Metachromatic Leukodystrophy (MLD) (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Metachromatic Leukodystrophy (MLD) (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Metachromatic Leukodystrophy (MLD) - Overview
    Metachromatic Leukodystrophy (MLD) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Metachromatic Leukodystrophy (MLD) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Metachromatic Leukodystrophy (MLD) - Companies Involved in Therapeutics Development
    ArmaGen Inc
    GlaxoSmithKline Plc
    Recursion Pharmaceuticals LLC
    RegenxBio Inc
    Shire Plc
    Metachromatic Leukodystrophy (MLD) - Drug Profiles
    AGT-183 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DUOC-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate Arylsulfatase A for Metachromatic Leukodystrophy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-2696274 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MGTA-456 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SHP-611 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Metachromatic leukodystrophy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Metachromatic Leukodystrophy (MLD) - Dormant Projects
    Metachromatic Leukodystrophy (MLD) - Discontinued Products
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Metachromatic Leukodystrophy (MLD) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Metachromatic Leukodystrophy (MLD) - Pipeline by ArmaGen Inc, H1 2017
    Metachromatic Leukodystrophy (MLD) - Pipeline by GlaxoSmithKline Plc, H1 2017
    Metachromatic Leukodystrophy (MLD) - Pipeline by Recursion Pharmaceuticals LLC, H1 2017
    Metachromatic Leukodystrophy (MLD) - Pipeline by RegenxBio Inc, H1 2017
    Metachromatic Leukodystrophy (MLD) - Pipeline by Shire Plc, H1 2017
    Metachromatic Leukodystrophy (MLD) - Dormant Projects, H1 2017
    Metachromatic Leukodystrophy (MLD) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Metachromatic Leukodystrophy (MLD) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    ArmaGen Inc
    GlaxoSmithKline Plc
    Recursion Pharmaceuticals LLC
    RegenxBio Inc
    Shire Plc

    Request for Sample

    Report Url http://www.reportsweb.com//metachromatic-leukodystrophy-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//metachromatic-leukodystrophy-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//metachromatic-leukodystrophy-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments